Back to Search
Start Over
753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
- Publication Year :
- 2023
- Publisher :
- BMJ Publishing Group, 2023.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 11
- Issue :
- Suppl 1
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.71c8f8460c0414cb01afc953fb43ffa
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2023-SITC2023.0753